FDA approves weekly Mimrylo injection for rare blood cancer
Protagonist developed the drug, which Takeda will sell under the Mimrylo brand.
Diagnostik, Prothesen, Impfstoffe, Genomik: die Medizin, die Lebensjahre gewinnt.
Medizin, die Lebensjahre gewinnt: KI-gestützte Vorsorge, die Millionen Patienten untersucht, Impfstoffe der neuen Generation, Genomik auf dem Weg von der Sequenzierung zur Therapie, Prothesen und Implantate, die verlorene Fähigkeiten zurückgeben. Die Rubrik verfolgt abgeschlossene klinische Studien, Marktzulassungen, Einführungen in Kliniken — den Moment, in dem eine Technologie aufhört, ein Paper zu sein, und zur Versorgung wird.
Die Zahlen entscheiden: Kohorten, Erkennungsraten, vermiedene Sterblichkeit, Kosten. Wir berichten gern über Gesundheitssysteme, die im großen Maßstab einführen — Indien, Brasilien, Südostasien —, weil sich sparsame Technologien oft dort bewähren, bevor sie anderswo ankommen. Jeder Artikel stützt sich auf die Studie, die Zulassung oder die Untersuchung dahinter — und nennt sie.
Protagonist developed the drug, which Takeda will sell under the Mimrylo brand.
UC Berkeley researchers compared eight Myotis genomes and found a link between longer life spans and cancer-fighting genes.
The 10-year STAREE trial followed nearly 10,000 independently living older adults in Australia.
A trial of 2,501 men found specialist referrals increased statin and blood-pressure treatment.
Danish registers followed 132,585 people diagnosed with type 2 diabetes from 2006 through 2019.
An exploratory analysis found a more favorable long-term quality-of-life trajectory with twice-daily radiation.
The 68 Ga/177 Lu-NYM096 pair uses one compound to image tumors and deliver targeted radiation.
Pacibekitug kept inflammation markers down through day 180 in adults with kidney disease and elevated inflammatory risk associated with heart disease.
TARGET-CTCA randomly assigned 3,170 people across 14 UK emergency departments.
MD Anderson researchers linked BRAF to the development and persistence of pain after nerve injury.
TU Wien researchers implanted cell-loaded DEGRAD INX scaffolds in a rabbit knee defect.
Abbott’s Libre Duo 10 Day reads ketones and glucose every minute for 10 days.
The open-label trial randomized 1,803 people at 18 South Korean centers to DOACs or no anticoagulation.
The University of Virginia team found 69.8% of patients had metastatic disease, including aggressive cancers such as pancreatic cancer.
The randomized trial enrolled 12 adults with drug-resistant epilepsy in Taiwan.
Boston University researchers identified lung-vein cells that become active after injury and promote scar formation.
The study covered 805 adults who received living-donor kidney transplants in Japan between 2001 and 2021.
Screening found HCV in 4.1% of people in custody, versus 0.3% in Hong Kong's general population.